ADHD
MCID: ATT013
MIFTS: 66

Attention Deficit-Hyperactivity Disorder (ADHD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 58 41
Attention Deficit Hyperactivity Disorder 42 12 77 38 30 6 44 15 64 17 74
Adhd 58 42 12 55 3 15
Attention Deficit-Hyperactivity Disorder, Susceptibility to 58 13 6
Attention Deficit Disorder 12 56 74
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 74
Attention Deficit Disorder with Hyperactivity 45
Attention-Deficit Hyperactivity Disorder 56
Hyperactivity of Childhood 58
Hyperkinetic Disorder 12

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
attention deficit-hyperactivity disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:1094
OMIM 58 143465
KEGG 38 H01895
MeSH 45 D001289
NCIt 51 C35092
ICD10 34 F90 F90.0 F90.9
MedGen 43 C1263846

Summaries for Attention Deficit-Hyperactivity Disorder

PubMed Health : 64 About attention deficit hyperactivity disorder: Attention deficit hyperactivity disorder, ADHD, is a mental disorder in which children are especially inattentive, impulsive or hyperactive. “Inattentive” refers to children who have difficulties focusing and are easily distracted. Overly “impulsive” children act in a way that is extremely rash, inconsiderate, careless or impatient for their age. “Hyperactive” describes children who are restless or constantly fidgeting – for instance, they may not be able to sit still during school lessons, and get up and walk around the classroom a lot instead.Severe ADHD can cause major problems in the life and everyday routine of both the child and their parents and brothers and sisters: Because children with ADHD behave differently than expected, they often cause trouble. They need a lot of attention. They find it more difficult to learn because of their short attention span. ADHD may also be accompanied by other kinds of mental disorders.The number of children being diagnosed with ADHD has increased in recent years. Some people are wary of this development and doubt that ADHD is really that common. They are worried that a lot of children who are diagnosed with ADHD are simply a little overactive, but otherwise healthy. A wrong diagnosis may lead to unnecessary treatment. Being wrongly labelled as mentally ill may also affect a child’s self-esteem.But there are also children and teenagers who actually have ADHD but are not diagnosed with it. This can also have a negative effect, because they may not get treatment that could help them. So it is very important to take the time to look into things so ADHD can be ruled out or diagnosed.

MalaCards based summary : Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to gilles de la tourette syndrome and oppositional defiant disorder, and has symptoms including seizures, tremor and back pain. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Dopaminergic synapse and Serotonergic synapse. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and thyroid, and related phenotypes are attention deficit hyperactivity disorder and hyperactivity

Disease Ontology : 12 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone and symptoms starting before seven years of age.

MedlinePlus : 44 Is it hard for your child to sit still? Does your child act without thinking first? Does your child start but not finish things? If so, your child may have attention deficit hyperactivity disorder (ADHD). Nearly everyone shows some of these behaviors at times, but ADHD lasts more than 6 months and causes problems in school, at home and in social situations. ADHD is more common in boys than girls. It affects 3-5 percent of all American children. The main features of ADHD are Inattention Hyperactivity Impulsivity No one knows exactly what causes ADHD. It sometimes runs in families, so genetics may be a factor. There may also be environmental factors. A complete evaluation by a trained professional is the only way to know for sure if your child has ADHD. Treatment may include medicine to control symptoms, therapy, or both. Structure at home and at school is important. Parent training may also help. NIH: National Institute of Mental Health

CDC : 3 People with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active. Although ADHD can’t be cured, it can be successfully managed and some symptoms may improve as the child ages.

NINDS : 55 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

Wikipedia : 77 Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It... more...

Description from OMIM: 143465

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases in the Attention Deficit-Hyperactivity Disorder family:

Attention Deficit-Hyperactivity Disorder 1 Attention Deficit-Hyperactivity Disorder 2
Attention Deficit-Hyperactivity Disorder 3 Attention Deficit-Hyperactivity Disorder 4

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 gilles de la tourette syndrome 33.7 COMT DRD4 DRD5 SLC6A3
2 oppositional defiant disorder 32.6 COMT DRD4 SLC6A2 SLC6A3 TPH2
3 conduct disorder 32.5 COMT DRD4 DRD5 SLC6A3
4 personality disorder 32.3 COMT DRD4 SLC6A3
5 obsessive-compulsive disorder 32.2 CDK20 COMT DRD4 HIVEP1 SLC6A3 TPH2
6 tic disorder 32.2 DRD4 DRD5 SLC6A3 TPH2
7 disease of mental health 32.1 COMT DRD4 MECP2 SLC6A2 SLC6A3
8 schizophrenia 32.0 COMT DRD4 DRD5 MECP2 SLC6A2 SLC6A3
9 substance abuse 31.9 COMT DRD4 DRD5 SLC6A3
10 mood disorder 31.9 COMT DRD4 SLC6A2 TPH2
11 alcohol dependence 31.8 COMT DRD4 SLC6A3 TPH2
12 major depressive disorder 31.7 COMT DRD4 SLC6A2 SLC6A3 TPH2
13 alacrima, achalasia, and mental retardation syndrome 31.6 C12orf57 MECP2 VPS13B
14 mental depression 31.5 COMT SLC6A2 TPH2
15 substance dependence 31.4 DRD4 DRD5 SLC6A3
16 panic disorder 31.2 COMT SLC6A2 TPH2
17 psychotic disorder 30.8 COMT DRD4 SLC6A3
18 pathological gambling 30.1 DRD4 SLC6A3
19 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 13.0
20 attention deficit-hyperactivity disorder 2 12.9
21 attention deficit-hyperactivity disorder 1 12.7
22 attention deficit-hyperactivity disorder 4 12.7
23 attention deficit-hyperactivity disorder 3 12.7
24 pol iii-related leukodystrophies 12.4
25 aarskog-scott syndrome 11.9
26 learning disability 11.8
27 asperger syndrome 11.7
28 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.6
29 intellectual developmental disorder and retinitis pigmentosa 11.5
30 microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum 11.5
31 thyroid hormone resistance, generalized, autosomal dominant 11.3
32 epilepsy, focal, with speech disorder and with or without mental retardation 11.3
33 cerebral creatine deficiency syndrome 1 11.3
34 legius syndrome 11.3
35 chromosome 1q21.1 deletion syndrome, 1.35-mb 11.3
36 chromosome 16p11.2 deletion syndrome, 220-kb 11.3
37 chromosome 15q11.2 deletion syndrome 11.3
38 smith-kingsmore syndrome 11.3
39 intellectual developmental disorder with gastrointestinal difficulties and high pain threshold 11.3
40 intellectual developmental disorder with speech delay, dysmorphic facies, and t-cell abnormalities 11.3
41 periventricular nodular heterotopia 8 11.3
42 impulse control disorder 11.3
43 15q13.3 microduplication syndrome 11.3
44 16p13.11 microduplication syndrome 11.3
45 bain type of x-linked syndromic intellectual disability 11.3
46 chromosome 17q11.2 deletion syndrome 11.3
47 xp22.3 microdeletion syndrome 11.3
48 autism 11.2
49 autism spectrum disorder 11.1
50 cognitive impairment with or without cerebellar ataxia 11.1

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:



Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

33
# Description HPO Frequency HPO Source Accession
1 attention deficit hyperactivity disorder 33 HP:0007018
2 hyperactivity 33 HP:0000752

Symptoms via clinical synopsis from OMIM:

58
Neuro:
hyperactivity

Misc:
male:female ratio 8:1

Clinical features from OMIM:

143465

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Attention Deficit-Hyperactivity Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 COMT DOCK3 DRD4 DRD5 GNB5 MECP2
2 nervous system MP:0003631 9.36 CDK20 COMT DOCK3 DRD4 DRD5 GNB5

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

PubMedHealth treatment related to Attention Deficit-Hyperactivity Disorder: 64

Before any treatment is started, the doctor will talk about what ADHD is and how everyone can best cope with it. As well as the parents and their child, teachers and preschool teachers may also be there too. It may then turn out that there is no urgent need for treatment. When deciding whether or not treatment is necessary, it is important to consider how much of a problem the behavior is for the child and their parents, and whether things like their performance at school are suffering as a result.If a child only has a mild form of ADHD that does not affect his or her life too much, it might be enough to complete a parent training and education program on dealing with ADHD. These programs can be taken as a class with an instructor or done on your own using written material.If a child has moderate or severe ADHD that is causing problems at school and in their social environment, it may be helpful to try interventions at school or have family or behavioral therapy. The type of help that will be most effective will depend on the child’s age, whether they tend to be more inattentive or more hyperactive, and what areas of their life the ADHD has the greatest impact on.Medication can relieve ADHD symptoms. It is mainly considered for the treatment of more severe ADHD when psychological and educational approaches are not effective enough. Medicine containing the drug methylphenidate is the most commonly used medication. If methylphenidate does not work or cannot be used for other reasons, the drugs atomoxetine, dexamfetamine or lisdexamfetamine may be used instead.Treatment at a psychosomatic or psychiatric hospital for children and teenagers may be a good idea for children who are extremely hyperactive and impulsive and have great difficulty coping in daily life, or can no longer cope at all. Hospital treatment may also be needed if the child has other severe mental disorders too.

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 403)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
3
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-41-2 439260
4
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
5
Dextroamphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-64-9 5826
6
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
7
Clonidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 4205-90-7 2803
8
Ziprasidone Approved Phase 4,Phase 2 146939-27-7 60854
9
Lithium carbonate Approved Phase 4,Phase 3 554-13-2
10
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
11
Topiramate Approved Phase 4 97240-79-4 5284627
12
Sertraline Approved Phase 4 79617-96-2 68617
13
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
14
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
17
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
18
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29110-47-2 3519
19
Methamphetamine Approved, Illicit Phase 4,Phase 2,Not Applicable 537-46-2 10836
20
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 300-62-9 3007 5826
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
22
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
23
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 1 16590-41-3 5360515
24
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
25
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 3 1406-66-2 14986
26
Galantamine Approved Phase 4 357-70-0 9651
27
Bupropion Approved Phase 4,Phase 3,Phase 2,Not Applicable 34841-39-9, 34911-55-2 444
28
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable 54-11-5 89594 942
29
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
30
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 51-45-6 774
31
Cyproheptadine Approved Phase 4 129-03-3 2913
32
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
33
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
34
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
35
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
36
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 439-14-5 3016
37
Oxcarbazepine Approved Phase 4 28721-07-5 34312
38
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
39
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
40
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
41
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
42
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
44
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
45
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
46
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
47
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
48
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73-31-4 896
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 1406-16-2
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 1308)
# Name Status NCT ID Phase Drugs
1 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4 Melatonin;Methylphenidate
2 Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers Unknown status NCT02623114 Phase 4 methylphenidate;atomoxetine
3 Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01339286 Phase 4 atomoxetine
4 Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD Unknown status NCT02074228 Phase 4 Methylphenidate (Concerta)
5 Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD) Unknown status NCT00862108 Phase 4 Methylphenidate
6 Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
7 A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD Unknown status NCT02677519 Phase 4 Aptensio XR
8 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
9 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
10 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
11 A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
12 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
13 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
14 Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4 atomoxetine
15 Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
16 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
17 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
18 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
19 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
20 Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed NCT01439126 Phase 4 clonidine hydrochloride;Placebo
21 Effect of Methylphenidate on Connectivity Withdrawn NCT01764672 Phase 4 Methylphenidate
22 Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response Recruiting NCT03153488 Phase 4 Methylphenidate LA (Ritalin);Mixed Amphetamine Salts XR (Adderall)
23 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4 Atomoxetine
24 Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Completed NCT00754208 Phase 4 methylphenidate
25 A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants Completed NCT01933880 Phase 4 Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
26 Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children Completed NCT01065259 Phase 4 OROS MPH;Atomoxetine
27 Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00783835 Phase 4 Long-Acting Methylphenidate
28 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4 Naltrexone
29 Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01238822 Phase 4 Methylphenidate;placebo;Methylphenidate;Methylphenidate
30 Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Completed NCT00760747 Phase 4 Atomoxetine
31 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
32 Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder Completed NCT00866996 Phase 4 Methylphenidate extended-release; Atomoxetine
33 A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder Completed NCT00518232 Phase 4 OROS-methylphenidate
34 Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Completed NCT01831622 Phase 4 Ritalin;Placebo
35 Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4 OROS-methylphenidate (Concerta)
36 A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Completed NCT00471354 Phase 4 Atomoxetine
37 A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. Withdrawn NCT03580005 Phase 4 methylphenidate HCl ERCT;Placebo
38 Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Completed NCT00753012 Phase 4 Lisdexamfetamine
39 An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01012622 Phase 4 Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
40 Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00937040 Phase 4 OROS MPH;Placebo;OROS MPH Tablets;Placebo Tablets
41 An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT01060150 Phase 4 OROS Methylphenidate HCl
42 Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse) Completed NCT01070394 Phase 4 LDX Treatment
43 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
44 Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD) Recruiting NCT00483106 Phase 4 Ritalin;Placebo
45 Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00856063 Phase 4 atomoxetine (or placebo)
46 Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01069523 Phase 4 Guanfacine Extended Release;Placebo
47 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder Completed NCT00429273 Phase 4 Guanfacine;Methylphenidate (MPH)
48 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00546910 Phase 4 Atomoxetine;Placebo
49 A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder Terminated NCT01721330 Phase 4 Naltrexone;Placebo
50 A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD Withdrawn NCT03536390 Phase 4 Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT);Placebo

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

# Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 30 DRD4 DRD5

Anatomical Context for Attention Deficit-Hyperactivity Disorder

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder:

42
Brain, Testes, Thyroid, Heart, Cortex, Eye, Bone

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 4983)
# Title Authors Year
1
Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: A nationwide cohort study. ( 30663207 )
2019
2
Attentional Control Explains Covariation Between Symptoms of Attention-Deficit/Hyperactivity Disorder and Anxiety During Adolescence. ( 31095814 )
2019
3
Effects of the Co-occurrence of Anxiety and Attention-Deficit/Hyperactivity Disorder on Intrinsic Functional Network Centrality among Children with Autism Spectrum Disorder. ( 31074587 )
2019
4
The importance of avoidant personality in social anxiety disorder with and without attention-deficit/hyperactivity disorder. ( 30767106 )
2019
5
Is there a prodrom period in patients with social anxiety disorder? A discussion on the hypothesis of social anxiety disorder development secondary to attention-deficit/hyperactivity disorder. ( 30604169 )
2019
6
Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review. ( 30422834 )
2019
7
Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study. ( 30949828 )
2019
8
Piloting a Sequential, Multiple Assignment, Randomized Trial for Mothers with Attention-Deficit/Hyperactivity Disorder and Their At-Risk Young Children. ( 30950637 )
2019
9
Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers. ( 30951155 )
2019
10
White matter microstructure is associated with hyperactive/inattentive symptomatology and polygenic risk for attention-deficit/hyperactivity disorder in a population-based sample of adolescents. ( 30952157 )
2019
11
The role of glutamate receptors in attention-deficit/hyperactivity disorder: From physiology to disease. ( 30953404 )
2019
12
Self-reported restless legs syndrome and involuntary leg movements during sleep are associated with symptoms of attention deficit hyperactivity disorder. ( 30954788 )
2019
13
Effect Modification by Attention Deficit Hyperactivity Disorder (ADHD) Symptoms on the Association of Psychosocial Work Environments With Psychological Distress and Work Engagement. ( 30971966 )
2019
14
Gender Effects in the Efficacy of Racemic Amphetamine Sulfate in Children with Attention-Deficit/Hyperactivity Disorder. ( 30972657 )
2019
15
STX1A gene variations contribute to the susceptibility of children attention-deficit/hyperactivity disorder: a case-control association study. ( 30976917 )
2019
16
JPP Student Journal Club Commentary: Technology Use and Sleep in Adolescents With and Without Attention-Deficit/Hyperactivity Disorder. ( 30977827 )
2019
17
Transcranial direct current stimulation in attention-deficit hyperactivity disorder: A meta-analysis of neuropsychological deficits. ( 30978259 )
2019
18
Utility of a novel simulator paradigm in the assessment of driving ability in individuals with and without attention-deficit hyperactivity disorder. ( 30980256 )
2019
19
Clinical diagnosis of attention-deficit/hyperactivity disorder in survivors of pediatric brain tumors. ( 30982198 )
2019
20
Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response. ( 30983465 )
2019
21
Use of Stimulants in Patients with Psychosis Having Past History of or Co-occurring Attention Deficit Hyperactivity Disorder: Is it Safe? ( 30983674 )
2019
22
Attention-Deficit Hyperactivity Disorder in Pediatric Patients With Type 1 Diabetes Mellitus: Clinical Outcomes and Diabetes Control. ( 30985385 )
2019
23
In-the-Moment Drinking Characteristics: An Examination Across Attention-Deficit/Hyperactivity Disorder History and Race. ( 30986327 )
2019
24
Dietary patterns and attention deficit/hyperactivity disorder (ADHD): A systematic review and meta-analysis. ( 30986731 )
2019
25
The impact of attention deficit hyperactivity disorder in obsessive-compulsive disorder subjects. ( 30990937 )
2019
26
Assessing causality in the association between attention-deficit/hyperactivity disorder and obesity: a Mendelian randomization study. ( 31000774 )
2019
27
Epigenome-wide Association Study of Attention-Deficit/Hyperactivity Disorder Symptoms in Adults. ( 31003786 )
2019
28
Temperament, executive function, and attention-deficit/hyperactivity disorder (ADHD) in adolescents: The mediating role of effortful control. ( 31007126 )
2019
29
Attention-deficit hyperactivity disorder symptomatology, binge eating disorder symptomatology, and body mass index among college students. ( 31009328 )
2019
30
Development and Validation of the Parental Smartphone Use Management Scale (PSUMS): Parents' Perceived Self-Efficacy with Adolescents with Attention Deficit Hyperactivity Disorder. ( 31010068 )
2019
31
The Functional Brain Organization of an Individual Allows Prediction of Measures of Social Abilities Transdiagnostically in Autism and Attention-Deficit/Hyperactivity Disorder. ( 31010580 )
2019
32
Positive effect of exogenous brain-derived neurotrophic factor on impaired neurite development and mitochondrial function in dopaminergic neurons derived from dental pulp stem cells from children with attention deficit hyperactivity disorder. ( 31010680 )
2019
33
Commentary on… the overlapping and distinct resting functional connectivity between autism spectrum disorder and attention-deficit hyperactivity disorder. ( 31014412 )
2019
34
Accumulated reinforcers increase academic responding and suppress problem behavior for students with Attention-Deficit Hyperactivity Disorder. ( 31016731 )
2019
35
Sex Differences in Comorbidity Patterns of Attention-Deficit/Hyperactivity Disorder. ( 30768399 )
2019
36
Self-reported attachment styles in children with and without attention-deficit/hyperactivity disorder (ADHD). ( 30770984 )
2019
37
Relationship between otorhinologic trauma and Attention Deficit Hyperactivity Disorder symptoms in children. ( 30772618 )
2019
38
Functional Connectivity of Frontoparietal and Salience/Ventral Attention Networks Have Independent Associations With Co-occurring Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Autism. ( 30777604 )
2019
39
Zebrafish models for attention deficit hyperactivity disorder (ADHD). ( 30779935 )
2019
40
Are subsyndromal manifestations of attention deficit hyperactivity disorder morbid in children? A systematic qualitative review of the literature with meta-analysis. ( 30780065 )
2019
41
Strategies for Coping with Time-Related and Productivity Challenges of Young People with Learning Disabilities and Attention-Deficit/Hyperactivity Disorder. ( 30781837 )
2019
42
Attention-Deficit Hyperactivity Disorder Symptom Status in a Mixed Gender Population of Opioid-Maintained Prison Inmates. ( 30783059 )
2019
43
Attention Deficit-Hyperactivity Disorder and Month of School Enrollment. ( 30785710 )
2019
44
Attention Deficit-Hyperactivity Disorder and Month of School Enrollment. ( 30785711 )
2019
45
Test of Everyday Attention for Children (TEA-Ch): Greek Normative Data and Discriminative Validity for Children with Combined Type of Attention Deficit-Hyperactivity Disorder. ( 30786760 )
2019
46
Cardiac Early Repolarization Pattern Anomalies Among Children and Adolescents With and Without Attention-Deficit Hyperactivity Disorder: A Community Observational Study. ( 30793013 )
2019
47
Dynamic connectivity and the effects of maturation in youth with attention deficit hyperactivity disorder. ( 30793080 )
2019
48
Abnormal functional network centrality in drug-naïve boys with attention-deficit/hyperactivity disorder. ( 30798413 )
2019
49
Early motor signs of attention-deficit hyperactivity disorder: a systematic review. ( 30798414 )
2019
50
Distinct Methylphenidate-Evoked Response Measured Using Functional Near-Infrared Spectroscopy During Go/No-Go Task as a Supporting Differential Diagnostic Tool Between Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder Comorbid Children. ( 30800062 )
2019

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

6 (show top 50) (show all 60)
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD5 DRD5, (CA)n MARKER undetermined variant risk factor
2 DRD4 DRD4, 120-BP INS insertion risk factor
3 VPS13B NM_017890.4(VPS13B): c.1219C> T (p.Gln407Ter) single nucleotide variant Pathogenic rs386834070 GRCh37 Chromosome 8, 100146872: 100146872
4 VPS13B NM_017890.4(VPS13B): c.1219C> T (p.Gln407Ter) single nucleotide variant Pathogenic rs386834070 GRCh38 Chromosome 8, 99134644: 99134644
5 MECP2 NM_004992.3(MECP2): c.1315G> A (p.Ala439Thr) single nucleotide variant Benign/Likely benign rs61753973 GRCh37 Chromosome X, 153295964: 153295964
6 MECP2 NM_004992.3(MECP2): c.1315G> A (p.Ala439Thr) single nucleotide variant Benign/Likely benign rs61753973 GRCh38 Chromosome X, 154030513: 154030513
7 C12orf4 NM_020374.4(C12orf4): c.639_640insACAA (p.Gln214Thrfs) insertion Pathogenic/Likely pathogenic rs730882197 GRCh38 Chromosome 12, 4525342: 4525343
8 C12orf4 NM_020374.4(C12orf4): c.639_640insACAA (p.Gln214Thrfs) insertion Pathogenic/Likely pathogenic rs730882197 GRCh37 Chromosome 12, 4634508: 4634509
9 CHAF1B NM_005441.2(CHAF1B): c.496A> G (p.Ile166Val) single nucleotide variant Likely pathogenic rs140630794 GRCh38 Chromosome 21, 36397429: 36397429
10 CHAF1B NM_005441.2(CHAF1B): c.496A> G (p.Ile166Val) single nucleotide variant Likely pathogenic rs140630794 GRCh37 Chromosome 21, 37769727: 37769727
11 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh38 Chromosome X, 154030644: 154030664
12 MECP2 NM_001110792.1(MECP2) indel Pathogenic rs786205019 GRCh37 Chromosome X, 153296095: 153296115
13 KIF5B NM_004521.2(KIF5B): c.2252A> G (p.His751Arg) single nucleotide variant Likely pathogenic rs1114167297 GRCh38 Chromosome 10, 32019912: 32019912
14 KIF5B NM_004521.2(KIF5B): c.2252A> G (p.His751Arg) single nucleotide variant Likely pathogenic rs1114167297 GRCh37 Chromosome 10, 32308840: 32308840
15 C12orf57 NM_138425.3(C12orf57): c.53-2A> G single nucleotide variant Pathogenic rs1114167293 GRCh37 Chromosome 12, 7053637: 7053637
16 C12orf57 NM_138425.3(C12orf57): c.53-2A> G single nucleotide variant Pathogenic rs1114167293 GRCh38 Chromosome 12, 6944474: 6944474
17 TMEM47 NM_031442.3(TMEM47): c.35G> C (p.Arg12Pro) single nucleotide variant Likely pathogenic rs1114167296 GRCh37 Chromosome X, 34675112: 34675112
18 TMEM47 NM_031442.3(TMEM47): c.35G> C (p.Arg12Pro) single nucleotide variant Likely pathogenic rs1114167296 GRCh38 Chromosome X, 34656995: 34656995
19 MAGED2 NM_201222.2(MAGED2): c.1003delC (p.Gln335Asnfs) deletion Likely pathogenic rs1114167295 GRCh38 Chromosome X, 54812169: 54812169
20 MAGED2 NM_201222.2(MAGED2): c.1003delC (p.Gln335Asnfs) deletion Likely pathogenic rs1114167295 GRCh37 Chromosome X, 54838602: 54838602
21 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic rs761399728 GRCh37 Chromosome 15, 52446144: 52446144
22 GNB5 NM_006578.3(GNB5): c.242C> T (p.Ser81Leu) single nucleotide variant Pathogenic rs761399728 GRCh38 Chromosome 15, 52153947: 52153947
23 46;XY;t(4;14)(p15.32;q32.1)dn Translocation Uncertain significance
24 46;XY;t(6;11)(q23;q21)or(q25;q21)dn Translocation Uncertain significance
25 Translocation Likely pathogenic
26 46;XX;t(9;19)(q22.3;q13.1)dn Translocation Uncertain significance
27 46;XY;t(8;10)(q13;p13)dn Translocation Pathogenic
28 46;XY;t(1;3)(p22;q21)dn Translocation Uncertain significance
29 46;XY;t(2;11)(q31;q13.5)pat Translocation Uncertain significance
30 46;XX;t(10;14)(p13;q21)dn Translocation Likely pathogenic
31 46;XX;inv(7)(q11.23q36.3)dn inversion Pathogenic
32 46;XY;t(20;22)(q13.3;q11.2) Translocation Uncertain significance
33 46;XY;t(3;5)(q24;p15.3)dn Translocation Pathogenic
34 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
35 46;XY;t(12;14)(q15;q13)mat Translocation Uncertain significance
36 46;XY;t(5;15)(q11.2;q24) Translocation Pathogenic
37 46;XY;inv(2)(q11.2q24.2)dn inversion Uncertain significance
38 46;XX;t(2;5)(q33;p15.3) Translocation Uncertain significance
39 46;X;inv(X)(q27q28) inversion Uncertain significance
40 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
41 DEAF1 NM_021008.3(DEAF1): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs1057518811 GRCh37 Chromosome 11, 686995: 686995
42 DEAF1 NM_021008.3(DEAF1): c.667G> A (p.Gly223Ser) single nucleotide variant Uncertain significance rs1057518811 GRCh38 Chromosome 11, 686995: 686995
43 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh37 Chromosome 6, 12124117: 12124117
44 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh38 Chromosome 6, 12123884: 12123884
45 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh37 Chromosome 9, 90584834: 90584834
46 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh38 Chromosome 9, 87969919: 87969919
47 SCAPER NM_020843.3(SCAPER): c.2973_2976del (p.Ile991Metfs) deletion Pathogenic rs1555447569 GRCh38 Chromosome 15, 76471314: 76471317
48 SCAPER NM_020843.3(SCAPER): c.2973_2976del (p.Ile991Metfs) deletion Pathogenic rs1555447569 GRCh37 Chromosome 15, 76763655: 76763658
49 CDRT4; HS3ST3B1; PMP22; TEKT3; TVP23C; TVP23C-CDRT4 GRCh37/hg19 17p12(chr17: 14215739-15422582) copy number loss Pathogenic GRCh37 Chromosome 17, 14215739: 15422582
50 CDRT4; HS3ST3B1; PMP22; TEKT3; TVP23C; TVP23C-CDRT4 GRCh37/hg19 17p12(chr17: 14215739-15422582) copy number loss Pathogenic GRCh37 Chromosome 17, 14215739: 15422582

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

7 (show top 50) (show all 84)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion USP24e Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication KDELC2 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or delet ion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or delet ion LHFP Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or delet ion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or delet ion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or delet ion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted ERK1 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication A2BP1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder